{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T17:40:18Z","timestamp":1737049218882,"version":"3.33.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"College of Medicine, University of Florida, through the Gatorade Trust Fund."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Cluster and contact investigations aim to identify and treat individuals with tuberculosis (TB) and latent TB infection (LTBI). Although genotyped cluster investigations may be superior to contact investigations in generating additional epidemiological links, this may not necessarily translate into reducing infections. Here, we investigated the impact of genotyped cluster investigations compared to standard contact investigations on the LTBI care cascade in a low incidence setting.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A matched case-control study nested within a cohort of 6,921\u00a0TB cases from Florida (2009\u20132023) was conducted. Cases (<jats:italic>n<\/jats:italic>\u2009=\u2009670) underwent genotyped cluster investigations, while controls (<jats:italic>n<\/jats:italic>\u2009=\u2009670) received standard contact investigations and were matched 1:1 by age. The LTBI care cascade outcomes were compared using Pearson\u2019s chi-square tests.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of the 5,767 identified contacts, 3,230 (56.0%) were associated with the case group, while 2,537 (44.0%) were identified in the control group. A higher proportion of contacts were evaluated in the control group (85.5%) than in the case group (81.5%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). While the proportion of evaluated contacts diagnosed with LTBI did not significantly differ between the groups (case: 20.4%, control: 21.5%, <jats:italic>p<\/jats:italic>\u2009=\u20090.088), a higher percentage of LTBI-diagnosed contacts initiated TB preventive treatment (TPT) in the control group (95.9%) than the case group (92.9%, <jats:italic>p<\/jats:italic>\u2009=\u20090.029). TPT completion rates were similar, with 65.2% in the case group and 66.3% in the control group (<jats:italic>p<\/jats:italic>\u2009=\u20090.055). TB patients in the case group were more likely to be males, U.S.-born, Asians, residents of long-term care or correctional facilities, with past year histories of alcohol use, homelessness, and drug use.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Despite the demographic and epidemiological differences between cases and controls, cluster investigations identified more contacts, with no significant difference in contacts diagnosed with LTBI, but were less effective than standard contact investigations in evaluating contacts, initiating LTBI treatment, and ensuring completion.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12879-024-10358-4","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T17:10:01Z","timestamp":1737047401000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genotyped cluster investigations versus standard contact tracing: comparative impact on latent tuberculosis infection cascade of care in a low-incidence region"],"prefix":"10.1186","volume":"25","author":[{"given":"Michael","family":"Asare-Baah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie Nancy","family":"S\u00e9raphin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"LaTweika A.T.","family":"Salmon-Trejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lori","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Dominique","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ashkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krishna","family":"Vaddiparti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Awewura","family":"Kwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony T.","family":"Maurelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Lauzardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"10358_CR1","unstructured":"DTBE Strategic Plan 2022\u20132026. https:\/\/www.cdc.gov\/tb\/about\/strategic-plan-background.htm#activities (Accessed Apr 02, 2024)."},{"key":"10358_CR2","doi-asserted-by":"publisher","unstructured":"Chapman HJ, Lauzardo M. Advances in diagnosis and treatment of latent tuberculosis infection. J Am Board Fam Med. Sep. 2014;27(5):704\u201312. https:\/\/doi.org\/10.3122\/JABFM.2014.05.140062.","DOI":"10.3122\/JABFM.2014.05.140062"},{"key":"10358_CR3","doi-asserted-by":"publisher","unstructured":"Ghosh S, Moonan PK, Cowan L, Grant J, Kammerer S, Navin TR. Tuberculosis genotyping Information Management System: enhancing tuberculosis surveillance in the United States, 2011, https:\/\/doi.org\/10.1016\/j.meegid.2011.10.013","DOI":"10.1016\/j.meegid.2011.10.013"},{"key":"10358_CR4","doi-asserted-by":"publisher","unstructured":"Wortham JM, Li R, Althomsons SP, Kammerer S, Haddad MB, Powell KM. Tuberculosis Genotype Clusters and Transmission in the U.S., 2009\u20132018, Am. J. Prev. Med., vol. 61, no. 2, pp. 201\u2013208, Aug. 2021, https:\/\/doi.org\/10.1016\/j.amepre.2021.02.006","DOI":"10.1016\/j.amepre.2021.02.006"},{"key":"10358_CR5","unstructured":"National TB Controllers Association \/ CDC Advisory Group on Tuberculosis Genotyping. Guide to the Application of Genotyping to Tuberculosis Prevention and Control: Handbook for TB Controllers, Epidemiologists, Laboratorians, and Other Program Staff, 2004. Accessed: Feb. 01, 2023. [Online]. Available: http:\/\/web-tb.forum.cdc.gov"},{"key":"10358_CR6","unstructured":"Talarico S, Silk B, Branch OI, Shaw T, Cilnis M. Whole-genome sequencing for investigation of recent TB transmission in the United States: Current uses and future plans, 2022. Accessed: Oct. 28, 2022. [Online]. Available: https:\/\/www.cdc.gov\/tb\/programs\/genotyping\/Tuberculosis_WGS_Training_Module.pdf"},{"issue":"5","key":"10358_CR7","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.3201\/EID1205.050446","volume":"12","author":"CM Clark","year":"2006","unstructured":"Clark CM, et al. Universal genotyping in Tuberculosis Control Program. Emerg Infect Dis. 2006;12(5):2001\u20133. https:\/\/doi.org\/10.3201\/EID1205.050446.","journal-title":"Emerg Infect Dis"},{"key":"10358_CR8","doi-asserted-by":"publisher","unstructured":"Guthrie JL, et al. Universal genotyping for tuberculosis prevention programs: a 5-year comparison with on-request genotyping. J Clin Microbiol. May 2018;56(5). https:\/\/doi.org\/10.1128\/JCM.01778-17.","DOI":"10.1128\/JCM.01778-17"},{"key":"10358_CR9","doi-asserted-by":"publisher","unstructured":"Holzman SB et al. Nov., Evaluation of the Latent Tuberculosis Care Cascade Among Public Health Clinics in the United States, Clin. Infect. Dis., vol. 75, no. 10, pp. 1792\u20131799, 2022, https:\/\/doi.org\/10.1093\/CID\/CIAC248","DOI":"10.1093\/CID\/CIAC248"},{"key":"10358_CR10","doi-asserted-by":"publisher","unstructured":"Wilson JW, Kissner DG, Escalante P. Cascade of care in the management of latent tuberculosis infection in the United States: a lot to improve and to scale up. Ann Am Thorac Soc. Oct. 2021;18(10):1620\u20131. https:\/\/doi.org\/10.1513\/ANNALSATS.202106-722ED\/SUPPL_FILE\/DISCLOSURES.PDF.","DOI":"10.1513\/ANNALSATS.202106-722ED\/SUPPL_FILE\/DISCLOSURES.PDF"},{"key":"10358_CR11","doi-asserted-by":"publisher","unstructured":"Alsdurf H, Hill PC, Matteelli A, Getahun H, Menzies D. The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis. Lancet Infect Dis. Nov. 2016;16(11):1269\u201378. https:\/\/doi.org\/10.1016\/S1473-3099(16)30216-X.","DOI":"10.1016\/S1473-3099(16)30216-X"},{"key":"10358_CR12","unstructured":"CDC. Tuberculosis Genotyping in the United States, 2004\u20132010, Atlanta, GA U.S. Dep. Heal. Hum. Serv. CDC, 2012, [Online]. Available: https:\/\/www.ptonline.com\/articles\/how-to-get-better-mfi-results"},{"key":"10358_CR13","unstructured":"CDC, Reported. TB in the US 2022 | Data & Statistics | TB | CDC, 2020. https:\/\/www.cdc.gov\/tb\/statistics\/reports\/2022\/genotyping.htm (accessed Mar. 27, 2024)."},{"key":"10358_CR14","unstructured":"CDC. Prioritizing Tuberculosis Genotype Clusters for Further Investigation & Public Health Action, 2017. Accessed: Jan. 08, 2023. [Online]. Available: http:\/\/www.cdc.gov\/tb\/programs\/genotyping\/default.htm"},{"issue":"4","key":"10358_CR15","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.meegid.2011.10.013","volume":"12","author":"S Ghosh","year":"2012","unstructured":"Ghosh S, Moonan PK, Cowan L, Grant J, Kammerer S, Navin TR. Tuberculosis genotyping Information Management System: enhancing tuberculosis surveillance in the United States. Infect Genet Evol. 2012;12(4):782\u20138. https:\/\/doi.org\/10.1016\/j.meegid.2011.10.013.","journal-title":"Infect Genet Evol"},{"key":"10358_CR16","doi-asserted-by":"publisher","unstructured":"Hanrahan CF et al. Apr., Household- Versus Incentive-Based Contact Investigation for Tuberculosis in Rural South Africa: A Cluster-Randomized Trial, Clin. Infect. Dis., vol. 76, no. 7, pp. 1164\u20131172, 2023, https:\/\/doi.org\/10.1093\/CID\/CIAC920","DOI":"10.1093\/CID\/CIAC920"},{"key":"10358_CR17","doi-asserted-by":"publisher","unstructured":"Hamblion EL, et al. Public health outcome of tuberculosis cluster investigations, England 2010\u20132013. J Infect. Apr. 2019;78(4):269\u201374. https:\/\/doi.org\/10.1016\/j.jinf.2018.12.004.","DOI":"10.1016\/j.jinf.2018.12.004"},{"key":"10358_CR18","doi-asserted-by":"publisher","unstructured":"Kato-Maeda M, Metcalfe JZ, Flores L. Genotyping of Mycobacterium tuberculosis: Application in epidemiologic studies, Future Microbiology, vol. 6, no. 2. NIH Public Access, pp. 203\u2013216, Feb. 2011. https:\/\/doi.org\/10.2217\/fmb.10.165","DOI":"10.2217\/fmb.10.165"},{"key":"10358_CR19","doi-asserted-by":"publisher","unstructured":"Teeter LD, et al. Validation of genotype cluster investigations for Mycobacterium tuberculosis: application results for 44 clusters from four heterogeneous United States jurisdictions. BMC Infect Dis. Oct. 2016;16(1):1\u201311. https:\/\/doi.org\/10.1186\/s12879-016-1937-9.","DOI":"10.1186\/s12879-016-1937-9"},{"issue":"5","key":"10358_CR20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1473-3099(14)70022-2","volume":"14","author":"LF Anderson","year":"2014","unstructured":"Anderson LF, et al. Transmission of multidrug-resistant tuberculosis in the UK: a cross-sectional molecular and epidemiological study of clustering and contact tracing. Lancet Infect Dis. 2014;14(5):406\u201315. https:\/\/doi.org\/10.1016\/S1473-3099(14)70022-2.","journal-title":"Lancet Infect Dis"},{"key":"10358_CR21","unstructured":"Service IH. LTBI Cascade of Care, 2017."},{"key":"10358_CR22","unstructured":"CDC. 2020 Report of Verified Case of Tuberculosis (RVCT) Instruction Manual, 2020."},{"key":"10358_CR23","unstructured":"CDC, TB GIMS | Data & Statistics | TB | CDC., 2024. https:\/\/www.cdc.gov\/tb\/publications\/factsheets\/statistics\/gims.htm (accessed Feb. 02, 2024)."},{"key":"10358_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v042.i08","volume":"42","author":"DE Ho","year":"2011","unstructured":"Ho DE, Imai K, King G, Stuart EA. MatchIt: nonparametric preprocessing for parametric causal inference. J Stat Softw. 2011;42:1\u201328. https:\/\/doi.org\/10.18637\/jss.v042.i08.","journal-title":"J Stat Softw"},{"key":"10358_CR25","unstructured":"matchit function - RDocumentation. https:\/\/www.rdocumentation.org\/packages\/MatchIt\/versions\/4.0.0\/topics\/matchit (Accessed Jul 13, 2023)."},{"key":"10358_CR26","doi-asserted-by":"publisher","unstructured":"Cronin WA et al. Nov., Molecular epidemiology of tuberculosis in a low-to moderate-incidence state: Are contact investigations enough? Emerg. Infect. Dis., vol. 8, no. 11, pp. 1271\u20131279, 2002, https:\/\/doi.org\/10.3201\/eid0811.020261","DOI":"10.3201\/eid0811.020261"},{"key":"10358_CR27","doi-asserted-by":"publisher","unstructured":"Miller AC et al. Nov., Impact of genotyping of Mycobacterium tuberculosis on public health practice in Massachusetts, Emerg. Infect. Dis., vol. 8, no. 11, pp. 1285\u20131289, 2002, https:\/\/doi.org\/10.3201\/eid0811.020316","DOI":"10.3201\/eid0811.020316"},{"key":"10358_CR28","doi-asserted-by":"publisher","unstructured":"McNabb SJN et al. Sep., Added Epidemiologic Value to Tuberculosis Prevention and Control of the Investigation of Clustered Genotypes of Mycobacterium tuberculosis Isolates, Am. J. Epidemiol., vol. 160, no. 6, pp. 589\u2013597, 2004, https:\/\/doi.org\/10.1093\/AJE\/KWH253","DOI":"10.1093\/AJE\/KWH253"},{"key":"10358_CR29","doi-asserted-by":"publisher","unstructured":"Sloot R, Van Der Loeff MFS, Kouw PM, Borgdorff MW. Risk of tuberculosis after recent exposure: A 10-year follow-up study of contacts in Amsterdam, Am. J. Respir. Crit. Care Med., vol. 190, no. 9, pp. 1044\u20131052, Nov. 2014, https:\/\/doi.org\/10.1164\/rccm.201406-1159OC","DOI":"10.1164\/rccm.201406-1159OC"},{"key":"10358_CR30","first-page":"RR","volume":"54","author":"MW Report","year":"2005","unstructured":"Report MW. Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC. MMWR Recomm Rep. 2005;54:RR.","journal-title":"MMWR Recomm Rep"},{"key":"10358_CR31","doi-asserted-by":"publisher","unstructured":"American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America: Controlling tuberculosis in the United States, American Journal of Respiratory and Critical Care Medicine, vol. 172, no. 9. pp. 1169\u20131227, Nov. 01. 2005. https:\/\/doi.org\/10.1164\/rccm.2508001","DOI":"10.1164\/rccm.2508001"},{"key":"10358_CR32","unstructured":"Lambregts-Van CSB, Weezenbeek et al. Tuberculosis contact investigation and DNA fingerprint surveillance in The Netherlands: 6 Years\u2019 experience with nation-wide cluster feedback and cluster monitoring, Int. J. Tuberc. Lung Dis., vol. 7, no. 12 SUPPL. 3, pp. 463\u2013470, 2003."},{"issue":"3","key":"10358_CR33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1093\/molbev\/msy242","volume":"36","author":"J Stimson","year":"2019","unstructured":"Stimson J, Gardy J, Mathema B, Crudu V, Cohen T, Colijn C. Beyond the SNP threshold: identifying outbreak clusters using inferred transmissions. Mol Biol Evol. 2019;36(3):587\u2013603. https:\/\/doi.org\/10.1093\/molbev\/msy242.","journal-title":"Mol Biol Evol"},{"key":"10358_CR34","doi-asserted-by":"publisher","unstructured":"Strain Variation in the Mycobacterium tuberculosis Complex: Its Role in Biology, Epidemiology and Control, vol. 1019. 2017. https:\/\/doi.org\/10.1007\/978-3-319-64371-7","DOI":"10.1007\/978-3-319-64371-7"},{"key":"10358_CR35","doi-asserted-by":"publisher","unstructured":"Stuurman AL, Vonk Noordegraaf-Schouten M, van Kessel F, Oordt-Speets AM, Sandgren A, van der Werf MJ. Interventions for improving adherence to treatment for latent tuberculosis infection: A systematic review, BMC Infect. Dis., vol. 16, no. 1, Jun. 2016, https:\/\/doi.org\/10.1186\/s12879-016-1549-4","DOI":"10.1186\/s12879-016-1549-4"},{"key":"10358_CR36","doi-asserted-by":"publisher","unstructured":"Menzies D, et al. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. Nov. 2008;149(10):689\u201397. https:\/\/doi.org\/10.7326\/0003-4819-149-10-200811180-00003.","DOI":"10.7326\/0003-4819-149-10-200811180-00003"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10358-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-10358-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10358-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T17:10:07Z","timestamp":1737047407000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-10358-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10358"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-10358-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"24 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the Institutional Review Board (IRB) of the University of Florida (approval number IRB201700445) and the Florida Department of Health (FDOH) TB Program as part of program evaluations and projects to improve the clinical and public health services of the state and local TB programs of the state of Florida (SOW21-473; 6.1.11.), for which informed consent was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}